[{"data":1,"prerenderedAt":73},["ShallowReactive",2],{"site":3,"pipeline":33},{"id":4,"aiSummary":5,"extension":6,"hero":7,"meta":13,"partnerSummary":14,"pipelineSummary":15,"positioning":16,"stats":17,"stem":30,"techSummary":31,"__hash__":32},"site\u002Fdata\u002Fsite.yml","AI\u002FML is embedded across the EMP™ discovery engine. Proprietary datasets generated by the platform feed task-specific models — including our internal StabLyzeGraph tool, co-developed with the Cosconati Lab — that guide design, ranking, and experimental planning. Lab in the loop, human in the loop.\n","yml",{"eyebrow":8,"headline":9,"subhead":10,"ctaPrimary":11,"ctaSecondary":12},"Discovery + Development","Unlocking the potential of membrane proteins.","Abilita Therapeutics is a discovery and development company drugging the most challenging targets in medicine — multi-span membrane proteins long considered intractable — through directed evolution and AI-guided design.\n","See the science","Explore the pipeline",{},"Collaborations with Lilly, Amgen, BMS, GSK, Regeneron, and Orion validate EMP™ across antibody and small-molecule discovery against historically undruggable targets.\n","Six programs spanning oncology and metabolic disease. Internal small molecules and antibodies on first-in-class targets; partnered campaigns with global pharma. Every program is built on an EMP-stabilised receptor.\n","Multi-span membrane proteins represent 60% of approved drug targets — yet only 15% of the more than 2,000 in the human proteome have ever been successfully drugged. Abilita's EMP™ platform turns the rest into tractable substrates for small-molecule, antibody, and ADC discovery.\n",[18,21,24,27],{"value":19,"label":20},"16","MMP targets stabilised",{"value":22,"label":23},"5","Internal discovery programs",{"value":25,"label":26},"2","Cryo-EM structures determined",{"value":28,"label":29},"60%","of approved drugs target MMPs","data\u002Fsite","At the core of Abilita is EMP™ — Enabled Membrane Protein technology — a directed-evolution approach that stabilises intractable receptors in defined active or inactive states. The result is a protein you can actually screen against, structure, and design drugs for.\n","4rj6hWVBosjyhY3SwXATa0CZso7rpw9B0KnFCEVyDwc",{"id":34,"extension":6,"meta":35,"rows":36,"stem":71,"__hash__":72},"pipeline\u002Fdata\u002Fpipeline.yml",{},[37,44,50,55,60,66],{"target":38,"indication":39,"modality":40,"phase":41,"track":42,"inflection":43},"GPR75","Obesity","Small molecule",0.55,"internal","In vitro Lead — 2H 2026",{"target":45,"indication":46,"modality":47,"phase":48,"track":42,"inflection":49},"GPR87","NSCLC, Head & Neck","mAb (ADCC or ADC)",0.45,"In vivo POC — 1H 2027",{"target":51,"indication":52,"modality":53,"phase":54,"track":42,"inflection":49},"GPR81","PDAC, TNBC","mAb",0.4,{"target":56,"indication":56,"modality":57,"phase":54,"track":58,"inflection":59},"Multiple","mAb \u002F ADC","partner","In vivo POC",{"target":61,"indication":62,"modality":53,"phase":63,"track":58,"inflection":64,"gated":65},"CCR8","CRC, SCLC, others",0.7,"Partnering activities ongoing",true,{"target":67,"indication":67,"modality":53,"phase":68,"track":58,"partnerName":69,"inflection":70},"Undisclosed",0.35,"Orion","Partnered at discovery stage","data\u002Fpipeline","HXmlOIwWoAkgK5oKn5yK4S9a-n2Br_vdWAD-kwGN2P4",1779487983544]